Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this ...

Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...

On October 8, 2024, PhRMA held a media briefing to address growing concerns over the Inflation Reduction Act (IRA) and its effects on the biopharmaceutical industry, Medicare Part D beneficiaries, and ...

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

Leaders of Gritstone Bio Inc. could read the writing on the wall: Financial times for drug developers are tough and the ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2025, according to Statista. A large portion of that figure is from the oncology segment, which is expected ...

Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDAInitiated ...

We recently made a list of Goldman Sachs’ List Of Stocks Popular With Mutual Fund Managers: Top 20 Stocks. In this piece, we ...